The Purple Sky Store
Women's Quarter Zip (Embroidered Purple Ribbon)
Women's Quarter Zip (Embroidered Purple Ribbon)
Couldn't load pickup availability
Blend style with purpose in the Champion Spirit Support Quarter Zip, a lightweight, versatile pullover ideal for streetwear or athletic wear. Crafted from 95% recycled polyester and 5% spandex, this quarter zip offers a comfortable athletic fit with just the right amount of stretch. The self-fabric cuffs and waistband provide a clean, streamlined look, while triple-needle stitch details add durability. Finished with Champion’s signature ‘C’ logo on the left sleeve, this pullover showcases quality and timeless design.
More than just a style staple, this quarter zip supports an important cause. 40% of all revenue from the Champion Spirit Support Quarter Zip goes to Sky Foundation, a non-profit that funds pancreatic cancer research, allowing every purchase to make an impact.
Made from 95% recycled polyester, 5% spandex for a lightweight, elastic feel
Fabric weight: 5.5 oz./yd² (186.48 g/m²) for all-day comfort
Athletic fit with self-fabric cuffs and waistband
Triple-needle stitch details for added durability at cuffs, waistband, shoulders, and back yoke
Heat-sealed neck label for a smooth finish
Share






Recent News
View all-
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
-
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
-
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...